Inference on Selected Subgroups in Clinical Trials
临床试验中经选择子群的统计推断AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要研究临床试验中所选子群的效应推断,直接关联治疗效应的选择后评估。
临床试验中经选择子群的统计推断AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
When existing clinical trial data suggest a promising subgroup, we must address the question of how good the selected subgroup really is. The usual statistical inference applied to the selected subgroup, assuming that the subgroup is chosen independent of the data, may lead to an overly optimistic evaluation of the selected subgroup. In this article, we address the issue of selection bias and develop a de-biasing bootstrap inference procedure for the best selected subgroup effect. The proposed inference procedure is model-free, easy to compute, and asymptotically sharp. We demonstrate the merit of our proposed method by reanalyzing the MONET1 trial and show that how the subgroup is selected post hoc should play an important role in any statistical analysis. Supplementary materials for this article are available online.